Sample Page
Author:
Thryv Therapeutics Inc.
Posted Date:
May 12, 2026
Thryv Therapeutics to Participate in UBS, RBC Capital Markets, and Jefferies Healthcare Conferences
Thryv Therapeutics Inc.
May 12, 2026
Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268
Thryv Therapeutics Inc.
April 22, 2026
